Literature DB >> 28125906

Difluoromethylornithine in cancer: new advances.

George A Alexiou1, Georgios D Lianos1, Vassileios Ragos1, Vasiliki Galani2, Athanassios P Kyritsis1.   

Abstract

Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis. Polyamines are important for cell survival, thus DFMO was studied as an anticancer agent and as a chemoprevention agent. DFMO exhibited mainly cytostatic activity and had single agent efficacy as well as activity in combination with other chemotherapeutic drugs for some cancers and leukemias. Herewith, we summarize the current knowledge of the anticancer and chemopreventive properties of DFMO and assess the status of clinical trials.

Entities:  

Keywords:  chemoprevention; clinical trial; colorectal cancer; difluoromethylornithine; glioma; pancreatic cancer

Mesh：

Substances：

Year:  2017        PMID： 28125906     DOI： 10.2217/fon-2016-0266

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  29 in total

1.  Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses.

Authors:  Kshipra Singh; Lori A Coburn; Mohammad Asim; Daniel P Barry; Margaret M Allaman; Chanjuan Shi; M Kay Washington; Paula B Luis; Claus Schneider; Alberto G Delgado; M Blanca Piazuelo; John L Cleveland; Alain P Gobert; Keith T Wilson
Journal:  Cancer Res       Date:  2018-05-31       Impact factor: 12.701

Review 2.  Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.

Authors:  Satyendra C Tripathi; Johannes F Fahrmann; Jody V Vykoukal; Jennifer B Dennison; Samir M Hanash
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-23

3.  Ornithine decarboxylase, the rate-limiting enzyme of polyamine synthesis, modifies brain pathology in a mouse model of tuberous sclerosis complex.

Authors:  David Kapfhamer; James McKenna; Caroline J Yoon; Tracy Murray-Stewart; Robert A Casero; Michael J Gambello
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

4.  PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness.

Authors:  Lisa Kaminski; Stéphanie Torrino; Maeva Dufies; Zied Djabari; Romain Haider; François-René Roustan; Emilie Jaune; Kathiane Laurent; Nicolas Nottet; Jean-François Michiels; Maeva Gesson; Stéphane Rocchi; Nathalie M Mazure; Matthieu Durand; Jean-François Tanti; Damien Ambrosetti; Stephan Clavel; Issam Ben-Sahra; Frédéric Bost
Journal:  Cancer Res       Date:  2019-05-07       Impact factor: 12.701

Review 5.  Polyamines and Their Role in Virus Infection.

Authors:  Bryan C Mounce; Michelle E Olsen; Marco Vignuzzi; John H Connor
Journal:  Microbiol Mol Biol Rev       Date:  2017-09-13       Impact factor: 11.056

6.  Hypusine biosynthesis in β cells links polyamine metabolism to facultative cellular proliferation to maintain glucose homeostasis.

Authors:  Esther M Levasseur; Kentaro Yamada; Annie R Piñeros; Wenting Wu; Farooq Syed; Kara S Orr; Emily Anderson-Baucum; Teresa L Mastracci; Bernhard Maier; Amber L Mosley; Yunlong Liu; Ernesto Bernal-Mizrachi; Laura C Alonso; Donald Scott; Adolfo Garcia-Ocaña; Sarah A Tersey; Raghavendra G Mirmira
Journal:  Sci Signal       Date:  2019-12-03       Impact factor: 8.192

Review 7.  Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut-From Gut to Brain?

Authors:  Hartmut H Glossmann; Oliver M D Lutz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-31       Impact factor: 5.555

Review 8.  Cellular and Animal Model Studies on the Growth Inhibitory Effects of Polyamine Analogues on Breast Cancer.

Authors:  T J Thomas; Thresia Thomas
Journal:  Med Sci (Basel)       Date:  2018-03-13

Review 9.  Oil for the cancer engine: The cross-talk between oncogenic signaling and polyamine metabolism.

Authors:  Amaia Arruabarrena-Aristorena; Amaia Zabala-Letona; Arkaitz Carracedo
Journal:  Sci Adv       Date:  2018-01-24       Impact factor: 14.136

10.  Ornithine decarboxylase as a therapeutic target for endometrial cancer.

Authors:  Hong Im Kim; Chad R Schultz; Andrea L Buras; Elizabeth Friedman; Alyssa Fedorko; Leigh Seamon; Gadisetti V R Chandramouli; G Larry Maxwell; André S Bachmann; John I Risinger
Journal:  PLoS One       Date:  2017-12-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.